Alshahrani, Awad
Kholaif, Naji
Al-Khnifsawi, Mutaz
Zarif, Hawazen
Mahzari, Moeber
Funding for this research was provided by:
Amryt Pharma
Article History
Received: 6 October 2023
Accepted: 6 December 2023
First Online: 2 January 2024
Change Date: 13 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-02816-x
Declarations
:
: Awad Alshahrani has no competing interests to declare. Mutaz Al-Khnifsawi has received honoraria from Amryt. Moeber Mahzari has no competing interests to declare. Naji Kholaif has received honorarium from Amryt, Novartis and Amgen. Hawazen Zarif has received honoraria from Amryt.
: This analysis was conducted as a retrospective study of normal patient care, approved by the King Abdullah International Medical Research Center Institutional Review Board (IRB/2441/23). The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All patients provided written consent for their details to be published in the current report. For pediatric patients, or in instances where patients died, consent was provided by patients’ estates and/or living relatives.